Millennium present data on kinase programs at EORTC-NCI-AACR meeting

Data presented at the EORTC NCI AACR meeting detail data and progress on Millennium kinase programs:
MLN8237 – Aurora A  – Phase II trials expected in late 2008/early 2009
TAK-285 – EGFR/HER dual kinase  -  Demonstrated good target specificity, pharmacokinetics and distribution and efficacy in EGFR- and HER2-expressing xenograft models
TAK-593 -VEGF/PDGF – Preclinical data show potent pseudo-irreversibility [...]

Boehringer Ingelheim provide update on kinase programs

Boehringer have provided a pipeline update including information on kinase inhibitors, and announces forthcoming presentations:
BIBW 2992 (Tovok) – EGFR/HER2 – Phase III study in NSCLC has commenced
BIBF 1120 – VEGFR, PDGFR, FGFR – Phase III in NSCLC is planned “in the near future”.
PLK-1 inhibitors – data to be presented at the upcoming 20th EORTC – [...]

GSK respond to negative NICE recommendation on Tykerb

GSK have responded to the NICE recommendationi that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials. The company says “we strongly believe that the wrong decision has been made for patients, doctors and the NHS”

GSKs Tykerb (lapatinib) effective in advanced head and neck cancer

Phase II data presented at the European of Medical Oncology (ESMO) show that GSK’s Tykerb (lapatinib) is effective in advanced head and neck cancer

Roche to present at ESMO

Roche have announced that 100+ abstracts on Roche medicines will be presented at the upcoming European Society for Medical Oncology (ESMO) meeting.

Key presentations include:
* Data from AVAiL, confirming the use of Avastin as first line treatment in NSCLC
* Phase III data on continuation of Herceptin treatment
* Phase II data data on the use of [...]

Wyeths EKB-569 safe in Phase I trials in Colorectal Cancer

Phase I data show Wyeths EGFR/HER2 inhibitor EKB-569 to be safe in colorectal cancer patients when administered in combination with capecitabine

Coadministration of IGF-1R inhibitor BMS-554417 with HER2 inhibitor BMS-599626 increases antiproliferative activity

Co administration of IGF-1R inhibitor, BMS-554417 with HER2 inhibitor BMS-599626 resulted in a synergistic antiproliferative effect in ovarian cancer cell lines.

Combination of a sheddase inhibitor INCB3619 with lapatinib improves anti-tumor effect

Researchers have shown that the addition of sheddase inhibitor INCB3619 to lapatinib treated cells increases antitumor activity

BMS ready to initiate Phase II trial of BMS-690514 in NSCLC

BMS are preparing to initiate a Phase II trial of pan-HER inhibitor BMS-690514 in NSCLC

Curis initiate Phase I with CUDC-101

Curis have initiated a phase I trial of EGFR2 (HER2)/HDAC  inhibitor CUDC-101 in patients with solid tumors